Filgrastim
- Generic Name
- Filgrastim
- Brand Names
- Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio, Filgrastim Hexal, Tevagrastim
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 121181-53-1
- Unique Ingredient Identifier
- PVI5M0M1GW
- Background
Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human G...
- Indication
Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
...
- Associated Conditions
- Congenital neutropenia, Cyclic neutropenia, Febrile Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Idiopathic neutropenia, Infection, Neutropenia
- Associated Therapies
- Mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis therapy
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-09-21
- Target Recruit Count
- 202
- Registration Number
- NCT00003838
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 87
- Registration Number
- NCT00005987
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-18
- Lead Sponsor
- Cancer and Leukemia Group B
- Target Recruit Count
- 47
- Registration Number
- NCT00006252
- Locations
- 🇺🇸
UMASS Memorial Cancer Center - University Campus, Worcester, Massachusetts, United States
🇺🇸Cancer Institute of New Jersey at the Cooper University Hospital - Voorhees, Voorhees, New Jersey, United States
🇺🇸UCSF Comprehensive Cancer Center, San Francisco, California, United States
Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 22
- Registration Number
- NCT00005984
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00001384
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
- Conditions
- Interventions
- Drug: F-18 FluorodeoxyglucoseBiological: therapeutic allogeneic lymphocytesProcedure: Peripheral Blood Stem Cell donationDrug: cyclophosphamideDrug: cyclosporineDrug: doxorubicin hydrochlorideDrug: etoposideDrug: fludarabine phosphateDrug: melphalanDrug: prednisoneDrug: sirolimusDrug: tacrolimusDrug: vincristine sulfateProcedure: peripheral blood stem cell transplantationDrug: Filgrastim
- First Posted Date
- 2002-08-16
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00043979
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial
- Conditions
- Interventions
- First Posted Date
- 2002-07-10
- Last Posted Date
- 2017-07-17
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 38
- Registration Number
- NCT00041470
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia
- First Posted Date
- 2002-06-04
- Last Posted Date
- 2015-09-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT00038610
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2010-02-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 44
- Registration Number
- NCT00035620
G-CSF to Treat Crohn's Disease
- Conditions
- First Posted Date
- 2001-10-26
- Last Posted Date
- 2017-07-02
- Target Recruit Count
- 23
- Registration Number
- NCT00025805
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.